Sorafenib tosylate pharma grade API is supplied as a crystalline 1:1 p-toluenesulfonate salt of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide, with molecular weights of 637.03 g mol⁻¹ for the tosylate and 464.83 g mol⁻¹ for the free base. Product variants are designated according to intended downstream route: oral tablet/capsule grade, granulation grade, and injectable grade. These grades contain the same molecular entity but differ in particle size distribution, bioburden, endotoxin, and residual solvent control. The API is manufactured and released under ICH Q7 GMP and is intended solely for further pharmaceutical processing into oral immediate-release tablets, capsules, granules, and parenteral preparations. The product is not a finished dosage form and is not intended for direct patient administration. Specification alignment follows ICH Q6A for solid-state form, assay, related substances, residual solvents, and microbial quality.

What Changes When Tosylate Salt Replaces Free Base in Oral Solid Dosage Processing?

Salt formation with p-toluenesulfonic acid alters compaction behavior and dissolution rate. Sorafenib free base is practically insoluble in water and exhibits poor flow and high elastic recovery during compression; the crystalline tosylate salt reduces punch sticking and improves tabletability on rotary tablet presses equipped with forced feeders and pre-compression stations. The 1:1 stoichiometry is confirmed by HPLC assay and counterion titration. XRPD and DSC are used to verify the absence of free-base domains, unreacted p-toluenesulfonic acid domains, and solvates. Oral tablets are commonly manufactured as 200 mg sorafenib tablets, expressed as free base equivalent; the corresponding commercial strength is 274 mg sorafenib tosylate. Typical tablet formulations include microcrystalline cellulose, croscarmellose sodium, hypromellose, and sodium lauryl sulfate. Dissolution testing under USP <711> is performed with apparatus 2 in a discriminating medium; the specification is selected to detect changes in particle size and salt form. Compared with alternative salt forms such as hydrochloride or mesylate, the tosylate salt has an established compendial and regulatory history for oral oncology products, reducing the impurity qualification burden when sourcing a multi-supplier API.

Sorafenib free base is rarely suitable for direct GMP manufacture of finished oral solid dosage forms because of poor tabletability and inconsistent blend uniformity. The tosylate salt provides a more compactable crystalline lattice and allows tablet press operation without excessive punch filming. Compared with amorphous sorafenib, the crystalline tosylate product reduces the risk of recrystallization-driven dissolution changes during storage, although the amorphous form may show transient apparent solubility advantages. Published data for direct comparison of alternative sorafenib salts in the same formulation is limited; changing salt form requires re-qualification of dissolution, stability, and impurity profiles under ICH Q6A and ICH Q3A.

Residual Solvent and Elemental Impurity Control in Multi-Source API Supply

Residual solvent release follows ICH Q3C with headspace GC-FID using compendial conditions. Salt formation may involve acetone, methanol, ethanol, or isopropanol; each solvent is controlled as Class 2 or Class 3 with the lower limit applied where solvent accumulation is possible. Elemental impurities are assessed under ICH Q3D and measured by ICP-MS according to USP <233>. The risk assessment for oral and injectable grades differs by route of administration, with injectable grade receiving a lower parenteral permitted daily exposure for Class 1, 2A, and 2B elements. Residual p-toluenesulfonic acid and related sulfonate esters are monitored by HPLC-UV and controlled under ICH M7 when mutagenic impurity assessment is triggered. A multi-source supply is qualified by comparing batch data against the approved reference profile under ICH Q6A and ICH Q3A, not by visual appearance or melting point alone.

Injectable-grade sorafenib tosylate is handled in ISO 14644-1 Grade C areas with Grade A local protection for open processing. The API is tested for bioburden before aseptic fill or terminal processing; when supplied as sterile powder, sterility testing follows USP <71>. Endotoxin acceptance is determined by USP <85> using the maximum intended dose and the K/M formula; no fixed API-only endotoxin limit is declared without a defined clinical dose. Because sorafenib tosylate remains practically insoluble in neutral aqueous media, parenteral formulation is limited to co-solvent, surfactant, or complexing systems, and published data for specific injectable finished product configurations is limited. The oral grade is not interchangeable with the injectable grade: oral grade lacks endotoxin control and does not meet the particulate matter requirements described in USP <788> after reconstitution. Subvisible particle counts are monitored by light obscuration and membrane microscopy after dispersion in the intended diluent. Container closure systems for injectable API are selected to limit moisture ingress under ICH Q1A(R2) long-term and accelerated conditions.

When Injectable-Grade API Is Compounded for Parenteral Use, Endotoxin and Particle Load Govern Feasibility

At the compounding stage, the selected vehicle must maintain chemical stability and subvisible particle counts throughout the infusion hold time. Terminal autoclaving may not be applicable and requires thermal degradation stress data; aseptic filtration through 0.22 µm membranes is commonly used after filter compatibility testing for adsorptive loss. Because the API has poor aqueous solubility, the filtration step may concentrate undissolved particulates on the membrane, raising backpressure and reducing recoverable dose. The endotoxin limit for the formulated solution is derived from the maximum dose per kilogram and is not a fixed concentration; it is verified by the limulus amebocyte lysate test under USP <85> after validation of product-specific interference. Injectable-grade material is released with bioburden, endotoxin, and subvisible particle data, while oral-grade material is released only with total aerobic microbial count, total yeast and mold count, and specified organisms under USP <61> and USP <62>.

For granule production, the oral tablet grade is mixed with intragranular disintegrants and binders before high-shear wet granulation or roller compaction. The granulation grade is supplied with a controlled fines fraction to reduce segregation in low-shear bin blenders and to prevent dusting during vacuum transfer. Roller compaction is preferred over slugging because the crystalline tosylate salt exhibits brittle fracture, producing ribbons of uniform density at lower roll pressure than the free base. Ribbon milling through a 1.0 mm screen followed by blending with extragranular disintegrant provides granules with acceptable compressibility. Loss on drying is controlled before granulation; when the API exceeds the approved moisture limit, vacuum tray drying at or below 40°C is required before dispensing. Granules are tested for bulk and tapped density, compressibility index, and Hausner ratio to confirm consistent flow into tablet presses and capsule filling machines.

Micronized Surface Energy and Cohesive Bridging Limit Dry Granulation Throughput

Excessive particle size reduction increases surface energy and cohesive bridging in hopper throats, feed frames, and roller compactor inlet zones. The condition is monitored as increasing powder bed torque in high-shear mixers, variable ribbon edge density, and segregation of fines during bin blending. Equipment adjustments include reducing impeller speed during dry mixing, maintaining transfer equipment grounding, and controlling room humidity to reduce electrostatic charge. Magnesium stearate at 0.5–1.0% w/w is added by low-shear final blending to reduce sticking without forming a hydrophobic film that slows dissolution under USP <711>. Tablet press operators track ejection force and take-off torque to detect punch face buildup. When ejection force increases above the validated range, the press is stopped and the punch surfaces are cleaned; such excursions are recorded under 21 CFR 211.160 laboratory controls and 21 CFR 211.65 equipment maintenance. Capsule filling on auger or dosator systems uses the granulation grade because slug formation from cohesive powder causes weight variation beyond the acceptance limits of USP <905>.

Compatibility with common excipients has been evaluated through binary mixture studies. The product is incompatible with strong oxidizing agents and with acid-sensitive carrier systems that promote release of p-toluenesulfonic acid. Avoid combination with amine-based film coatings that may react with residual tosylate counterions during aqueous film coating; hypromellose-based systems with triethyl citrate or polyethylene glycol plasticizers are preferred. For oral solid dosage forms, the blend is protected from light and humidity; bulk packaging uses low-density polyethylene bags inside aluminum foil laminate to limit oxygen and moisture permeation. The API is labeled with a retest date based on ICH Q1A(R2) stability data generated in the same primary packaging configuration as commercial supply.